Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E.coli Nissle 1917 vs Lactulose and Rifaximin in Mild/Minimal Hepatic Encephalopathy
NCT04787276Completed
- Start
- Jan 2017
- Primary completion
- Jan 2020
- Modality
- Live Biotherapeutic Products
01
Overview
Trial of escherichia coli nissle 1917 in hepatic encephalopathy (HE) (3 arms). Primary endpoints: Change in Stroop test at 1 month and Change in serum ammonia at 1 month. Started Jan 2017; status: completed.
02
Drugs
escherichia coli nissle 1917
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT04787276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04787276.